• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by CohBar Inc. (Amendment)

    2/14/22 3:31:32 PM ET
    $CWBR
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $CWBR alert in real time by email
    SC 13G/A 1 tm226115d27_sc13ga.htm SC 13G/A

     

    CUSIP No: 19249J109

     

     

     

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT 

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED 

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    CohBar, Inc. 

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share 

    (Title of Class of Securities)

     

    19249J109 

    (CUSIP Number)

     

    December 31, 2021 

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No: 19249J109

     

      (1)

    NAMES OF REPORTING PERSONS

     

    CVI Investments, Inc.

     

      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
          (a)    ¨
          (b)    ¨
           
      (3) SEC USE ONLY
         
      (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    (5) SOLE VOTING POWER
     
    0
     
    (6) SHARED VOTING POWER **
     
    4,519,746
     
    (7) SOLE DISPOSITIVE POWER
     
    0
     
    (8) SHARED DISPOSITIVE POWER **
     
    4,519,746

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
        4,519,746
         
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨ 
         
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
         
        4.9%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 19249J109

     

      (1)

    NAMES OF REPORTING PERSONS

     

    Heights Capital Management, Inc.

     

      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
          (a)    ¨
          (b)    ¨
           
      (3) SEC USE ONLY
         
      (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    (5) SOLE VOTING POWER
     
    0
     
    (6) SHARED VOTING POWER **
     
    4,519,746
     
    (7) SOLE DISPOSITIVE POWER
     
    0
     
    (8) SHARED DISPOSITIVE POWER **
     
    4,519,746

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
        4,519,746
         
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨ 
         
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
         
        4.9%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 19249J109

     

    Item 1.

     

    (a)Name of Issuer

     

    CohBar, Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    1455 Adams Drive, Suite 2050, Menlo Park, CA 94025

     

    Item 2(a).Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT 

    Ugland House 

    South Church Street 

    George Town 

    Grand Cayman 

    KY1-1104 

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250 

    San Francisco, California 94111

     

    Item 2(c).Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d) Title of Class of Securities

     

    Common stock, $0.001 par value per share

     

    Item 2(e)CUSIP Number

     

    19249J109

     

     

     

     

    CUSIP No: 19249J109

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)  ¨Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
        
    (b)  ¨Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
        
    (c)  ¨Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
        
    (d)  ¨Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
        
    (e)  ¨An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
        
    (f)  ¨An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
        
    (g)  ¨A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
        
    (h)  ¨A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
        
    (i)  ¨A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
        
    (j)  ¨A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
        
    (k)  ¨Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares (the “Warrants”). The Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 4.99%.

     

    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 indicates there were 86,056,322 Shares outstanding as of November 10, 2021.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

     

     

     

    CUSIP No: 19249J109

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 19249J109

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 11, 2022

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.
    pursuant to a Limited Power of Attorney, a copy of which was previously filed
      By: /s/ Brian Sopinsky
      Name: Brian Sopinsky
      Title: Secretary

     

    By: /s/ Brian Sopinsky      
    Name: Brian Sopinsky      
    Title: Secretary      

     

     

     

     

    CUSIP No: 19249J109

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*

     

    *Previously filed

     

     

     

    Get the next $CWBR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CWBR

    DatePrice TargetRatingAnalyst
    8/11/2021$5.00Speculative Buy → Buy
    WBB Securities
    More analyst ratings

    $CWBR
    Leadership Updates

    Live Leadership Updates

    See more
    • CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors

      MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced the appointment of Effie Tozzo, Ph.D. as an independent director on the company's Board, effective July 11, 2022. Dr. Tozzo brings extensive research and development experience at both established pharmaceutical and innovative biotechnology companies. "We are delighted to add Dr. Tozzo to our Board and will tap into her considerable expertise in advancing preclinical assets to the clini

      7/12/22 9:00:00 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Announces Changes to its Board of Directors and R&D Leadership

      Founding board members transition to reconstituted Scientific Advisory Board Kent Grindstaff, Ph.D. appointed as Senior Vice President of Research MENLO PARK, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced changes to its Board of Directors, Scientific Advisory Board (SAB), and R&D leadership. CohBar's founders Drs. Nir Barzilai, Pinchas Cohen, and John Amatruda have transitioned from the company's Board of Directors to a reconstituted SAB. The SAB will be comprised of experts in mitochondrial science and other dis

      12/17/21 9:00:00 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors

      MENLO PARK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Joanne Yun, Ph.D. as an independent director on the company's Board, effective September 14, 2021. Dr. Yun brings extensive research and development, commercial, and governance experience from the pharmaceutical industry. "We are very pleased to add Dr. Yun as an independent director and look forward to her strategic input as we continue to develop our diverse pipeline of novel mitochondria based therapeutics," said David Greenwood, Chair

      9/15/21 9:00:00 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CohBar Inc. (Amendment)

      SC 13G/A - CohBar, Inc. (0001522602) (Subject)

      2/8/23 9:00:30 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by CohBar Inc. (Amendment)

      SC 13G/A - CohBar, Inc. (0001522602) (Subject)

      2/8/23 9:00:30 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by CohBar Inc. (Amendment)

      SC 13G/A - CohBar, Inc. (0001522602) (Subject)

      2/14/22 3:31:32 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)

      Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 20, 2023, CohBar, Inc. (the "Company") was notified by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff's belief that the Company is a "public shell," and that the continued listing of the Company's securities is no longer warranted, and the Company's non-compliance with certain board and committee composition listing requirements under Nasdaq Listing Rule 5605 and certain of Nasdaq's filing requirements under Nasdaq Listing Rule 5250(c)(1)

      11/27/23 6:05:00 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Reports Second Quarter 2023 Financial Results

      MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and Financial Results Entered into Definitive Merger Agreement with Morphogenesis: In May 2023, CohBar announced that the company entered into a definitive merger agreement with a privately held biotechnology company, Morphogenesis, Inc. ("Morphogenesis"), for an all-stock transaction to advance a late-stage oncology pipeline. The combined company is expected to operate under the name "TuHURA Biosciences, Inc." and to trade on The Nasdaq Capital Market ("Nasdaq"). The transaction is exp

      8/14/23 4:01:05 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

      IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an immune checkpoint inhibitor (ICI) in patients who exhibited primary resistance to ICIs Translational biomarker data underscores IFx-Hu2.0 mechanism; Demonstrates activation of systemic tumor-specific immune responses Data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting TAMPA, Fa. and MENLO PARK, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. ("Morphogenesis"), a privately-held Phase 2/3 clinical-stage biotechnology compa

      6/5/23 8:05:22 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    SEC Filings

    See more
    • SEC Form 25-NSE filed by CohBar Inc.

      25-NSE - CohBar, Inc. (0001522602) (Subject)

      12/27/23 9:01:40 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - CohBar, Inc. (0001522602) (Filer)

      11/27/23 5:21:26 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Inc. filed SEC Form 8-K: Leadership Update, Other Events

      8-K - CohBar, Inc. (0001522602) (Filer)

      11/13/23 9:01:36 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CohBar upgraded by WBB Securities with a new price target

      WBB Securities upgraded CohBar from Speculative Buy to Buy and set a new price target of $5.00

      8/11/21 7:20:55 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Maxim Group initiated coverage on CohBar with a new price target

      Maxim Group initiated coverage of CohBar with a rating of Buy and set a new price target of $3.00

      4/23/21 9:00:48 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aegis Capital initiated coverage on CohBar with a new price target

      Aegis Capital initiated coverage of CohBar with a rating of Buy and set a new price target of $6.00

      3/15/21 11:37:59 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Sarret Joseph J. was granted 131,017 shares, increasing direct ownership by 655% to 151,017 units

      4 - CohBar, Inc. (0001522602) (Issuer)

      8/3/22 9:00:22 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: Biunno Jeffrey Francis was granted 26,203 shares, increasing direct ownership by 84% to 57,355 units

      4 - CohBar, Inc. (0001522602) (Issuer)

      8/3/22 9:00:26 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Tozzo Stephanie

      4 - CohBar, Inc. (0001522602) (Issuer)

      7/12/22 4:06:36 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    Financials

    Live finance-specific insights

    See more
    • Lifshitz Law PLLC Announces Investigations of CWBR, GHL, PDCE, and VECT

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

      6/3/23 8:17:00 PM ET
      $CWBR
      $GHL
      $PDCE
      $VECT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Investment Bankers/Brokers/Service
      Finance
    • CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

      Combined company will operate under the name "TuHURA Biosciences, Inc." and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merger – combined company expected to have cash runway through 2024Companies to hold a joint conference call and webcast today, Tuesday, May 23rd at 8:30 AM ET MENLO PARK, Calif. and TAMPA, Fla. , May 23, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) ("CohBar" or the "company") and Morphogenesis, Inc. ("M

      5/23/23 7:30:39 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

      MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress. "I'm pleased with the team's performance during the third quarter of 2022 in advancing our top priorities, including improving the formulation of CB5138-3, our product candidate for IPF," stated Dr. Joseph Sarret, Chief Executive Officer. "We continue to operate the company i

      11/8/22 4:03:07 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care